Chronic or repeated stress results in reduction of food intake and body weight in rats. Stress-induced anorexia has been attributed to increased corticotropin-releasing hormone (CRH) function in the central nervous system. To explore possible roles of other neuropeptides and peripheral hormones involved in food intake and energy utilization during continuing stress, we examined the impact of repeated immobilization stress on expression of mRNAs coding for CRH, neuropeptide Y (NPY), galanin and pro-opiomelanocortin (POMC) mRNAs in such hypothalamic nuclei as the paraventricular nucleus (PVN), arcuate nucleus (ARC) and dorsomedial hypothalamus (DMH), as well as plasma insulin and leptin concentrations. Changes in type 2 CRH receptor (CRHR-2) mRNA in the ventromedial hypothalamus (VMH), a possible target of anorectic CRH effect, were also examined. Rats were immobilized for 2 h daily for 6 days and sacrificed 24 h after the last immobilization. Immobilized rats had lower food intake and body weight and higher levels of PVN CRH mRNA than controls. Repeated immobiliza tion also lowered plasma insulin and leptin concentrations and VMH CRHR-2 mRNA levels. These results provide additional evidence linking VMH CRHR-2 mRNA levels to plasma leptin concentration. ARC NPY and DMH galanin mRNAs increased following repeated immobilization, while ARC POMC mRNA decreased. DMH NPY mRNA and ARC galanin mRNA were unaltered by immobilization. Since NPY and galanin are considered orexigenic, while the POMC-melanocortin-4 receptor system is apparently anorexigenic, the changes in neuropeptide mRNAs and VMH CRHR-2 mRNA may play counterregulatory roles against anorectic CRH effects.

Keywords:
Corticotropin-releasing hormone, Corticotropin- releasing hormone receptors, Stress, Food intake, Insulin, Leptin, Ventromedial nucleus, Arcuate nucleus, Neuropeptide Y, Galanin
1.
Luiten PGM, Horst GJ, Steffens AB: The hypothalamus, intrinsic connections and outflow pathways to the endocrine system in regulation to the control of feeding and metabolism. Neurobiol 1987;28:1–54.
2.
Morley JE: Neuropeptide regulation of appetite and weight. Endocr Rev 1987;8:256–287.
3.
Krahn DD, Gosnell BA, Grace M, Levine AS: CRF antagonist partially reverses CRF- and stress-induced effects of feeding. Brain Res Bull 1986;17:285–289.
4.
Shibasaki T, Yamauchi N, Kato Y, Masuda A, Imaki T, Hotta M, Demura H, Oono H, Ling N, Shizume K: Involvement of corticotropin-releasing factor in restraint stress-induced anorexia and reversion of anorexia by somatostatin in the rat. Life Sci 1988;43:1103–1110.
5.
Heinrichs SC, Cole BJ, Pich EM, Menzaghi F, Koob GF, Hauger RL: Endogenous corticotropin-releasing factor modulates feeding induced by neuropeptide Y or a tail-pinch stressor. Peptides 1992;13:879–884.
6.
Spina M, Merlo-Pich E, Chan RKW, Basso AM, Rivier J, Vale W, Koob GF: Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996;273:1561–1564.
7.
Chalmers DT, Lovenberg TW, DeSouza EB: Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression. J Neurosci 1995;15:6340–6350.
8.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nat 1994;372:425–432.
9.
Sahu A: Evidence suggesting that galanin (GAL), melanin-concentrating hormone (MCH), neurotensin (NT), proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signaling in the hypothalamus. Endocrinology 1998;139:795–798.
10.
Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG: Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996;98:1101–1106.
11.
Makino S, Nishiyama M, Asaba K, Gold PW, Hashimoto K: Altered expression of type 2 CRH receptor mRNA in the VMH by glucocorticoids and starvation. Am J Physiol 1998;275:R1138–R1145.
12.
Nishiyama M, Makino S, Asaba K, Hashimoto K: Leptin effects on the expression of corticotropin-releasing hormone receptor mRNA in the ventromedial hypothalamus in the rat. J Neuroendocrinol 1999;11:307–314.
13.
Kvetnansky R, Mikulaj L: Adrenal and urinary catecholamines in rats during adaptation to repeated immobilization stress. Endocrinology 1970;87:738–743.
14.
Larhammer DL, Ericsson A, Persson H: Structure and expression of the rat neuropeptide Y gene. Proc Natl Acad Sci USA 1987;84:2068–2072.
15.
Drouin J, Chamberland M, Charron J, Jeannotte L, Nemer M: Structure of the rat proopiomelanocortin (POMC) gene. FEBS Lett 1985;193:54–58.
16.
Kaplan LM, Spindel ER, Isselbacher KJ, Chin WW: Tissue-specific expression of the rat galanin gene. Proc Natl Acad Sci USA 1988;85:1065–1069.
17.
Jingami H, Mizuno N, Takahashi H, Shibahara S, Furutani Y, Imura H, Numa S: Cloning and sequence analysis of cDNA for rat corticotropin-releasing factor precursor. FEBS Lett 1985;191:63–66.
18.
Makino S, Smith MA, Gold PW: Increased expression of corticotropin-releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamic paraventricular nucleus during repeated stress: Association with reduction in glucocorticoid receptor mRNA levels. Endocrinology 1995;136:3299–3309.
19.
Eghbal-Ahmadi M, Hatalski CG, Avishai-Eliner S, Baram TZ: Corticotropin-releasing factor receptor type II (CRF2) messenger ribonucleic acid levels in the hypothalamic ventromedial nucleus of the infant rat are reduced by maternal deprivation. Endocrinology 1997;138:5048–5051.
20.
Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, Rivier J, Sawchenko PE, Vale W: Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995;378:287–292.
21.
Brady LS, Smith MA, Gold PW, Herkenham M: Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats. Neuroendocrinology 1990;52:441–447.
22.
McShane TM, Petersen SL, McCorne S, Keisler DH: Influence of food restriction on neuropeptide-Y, proopiomelanocortin, and luteinizing hormone-releasing hormone gene expression in sheep hypothalami. Biol Reprod 1993;49:831–839.
23.
Dallman MF, Strack AM, Akana SF, Bradbury MJ, Hanson ES, Scribner KA, Smith M: Feast and Famine. Critical role of glucocorticoids with insulin in daily energy flow. Front Neuroendocrinol 1993;14:303–347.
24.
Sahu A, Kalra SP: Neuropeptidergic regulation of feeding behavior: Neuropeptide Y. Trends Endocrinol Metab 1993;4:217–224.
25.
Schwartz MW, Dallma MF, Woods SC: Hypothalamic response to starvation: Implications for the study of wasting disorders. Am J Physiol 1995;269:R949–R957.
26.
Kim EM, Welch CC, Grace MK, Billington CJ, Levine AS: Chronic food restriction and acute food deprivation decrease mRNA levels of opioid peptides in arcuate nucleus. Am J Physiol 1996;270:R1019–R1024.
27.
Baubet V, Fevre-Montange M, Gay N, Debilly G, Bobillier P, Cespuglio R: Effects of an acute immobilization stress upon proopiomelanocortin (POMC) mRNA levels in the mediobasal hypothalamus: A quantitative in situ hybridization study. Mol Brain Res 1994;26:163–168.
28.
Larsen PJ, Mau SE: Effect of acute stress on the expression of hypothalamic messenger ribonucleic acids encoding the endogenous opioid precursors preproenkephalin A and proopiomelanocortin. Peptides 1994;15:783–790.
29.
Fan W, Boston BA, Kesternson RA, Hruby VJ, Cone RD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997;385:165–168.
30.
Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte D Jr, Woods SC, Seeley RJ, Weigle DS: Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996;45:531–535.
31.
Mizuno TM, Kleopoulos SP, Bergen HT, Roberts JL, Priest CA, Mobbs CV: Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting in ob/ob and db/db mice, but is stimulated by leptin. Diabetes 1997;47:294–297.
32.
Schwartz MW, Seeley RJ, Woods SC, Weigle DS, Campfield LA, Burn P, Baskin DG: Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 1997;46:2119–2123.
33.
Beaulieu S, Gagne B, Barden N: Glucocorticoid regulation of proopiomelanocortin messenger ribonucleic acid content of rat hypothalamus. Mol Endocrinol 1988;2:727–731.
34.
Tong Y, Couet J, Simard J, Pelletier G: Glucocorticoid regulation of proopiomelanocortin mRNA levels in rat arcuate nucleus. Mol Cell Neurosci 1990;1:78–83.
35.
Wardlaw SL, McCarthy KC, Conwell IM: Glucocorticoid regulation of hypothalamic proopiomelanocortin. Neuroendocrinology 1998;67:51–57.
36.
Bernardis LL, Bellinger LL: The dorsomedial hypothalamic nucleus revisited: 1998 update. Proc Soc Exp Biol Med 1998;218:284–306.
37.
Kesterson RA, Huszar D, Lynch CA, Simerly RB, Cone RD: Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol Endocrinol 1997;11:630–637.
38.
Kalra SP, Kalra PS: Nutritional infertility: The role of the interconnected hypothalamic neuropeptide Y-galanin-opioid network. Front Neuroendocrinol 1996;17:371–401.
39.
Tempel DL, Leibowitz SF: Diurnal variations in the feeding responses to norepinephrine, neuropeptide Y, and galanin in the PVN. Brain Res Bull 1990;25:821–825.
40.
Akabayashi A, Koenig JI, Watanabe Y, Alexander JT, Leibowitz SF: Galanin-containing neurons in the paraventricular nucleus: A neurochemical marker for fat injestion and body weight gain. Proc Natl Acad Sci USA 1994;91:10375–10379.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.